Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 394 results for "biocon"

DCGI Grants Permission For New Eye Drug Trial
Med India

DCGI Grants Permission For New Eye Drug Trial

Biocon and its Israeli partner Quark Pharmaceuticals to proceed with human clinical trials for a new drug candidate, 'QPI-1007' targeting orphan eye disease. Advertisement Orphan eye disease is a condition that affects fewer than 200,000 people nationwide. Med India, 1 day ago

92 images for biocon, 2 days ago
India Infoline, 2 days ago
Deccan Chronicle, 1 day ago
Hindu Business Line, 2 days ago, 2 days ago
Business Standard India, 2 days ago
International Business Times India, 2 days ago
Bio Spectrum Asia, 2 days ago, 2 days ago
Hindu Business Line, 2 days ago

Intimation regarding Analysts / Institutional Investors Meet (SCRIPCODE: 532523)

Cities Business & Finance ACCORD FINTECH BSE Online News India, June 24 -- Biocon Ltd has informed BSE regarding "Intimation regarding Analysts / Institutional
 HT Syndication1 day ago Biocon informs about press release  HT Syndication3 weeks ago

Biocon begins clinical trials for drug to treat rare eye disorder

Biopharma firm Biocon Ltd on Thursday said it has begun clinical trials for a drug jointly developed with US-based QuarK Pharmaceuticals to treat a rare eye disorder. India's drug controller cleared the phase-II and -III trials to be done locally ...
 Business Standard India2 days ago Drug to treat eye disease won't hit mkt before 2-3 yrs: Biocon  Money Control2 days ago

FDI in pharma via automatic route a welcome step: Biocon

The government eased foreign direct investment in pharma sector and Kiran Mazumdar Shaw of Biocon says it is a step in the right direction.
 Money Control5 days ago Easing of FDI in pharma welcome; need no restrictions: Biocon  Money Control5 days ago FDI in pharma most welcome; beware of higher drug prices: Biocon  Money Control5 days ago

Biocon, Quark get nod for trial of eye treatment

Biopharma major Biocon and its partner U.S.-based Quark Pharmaceuticals said on Thursday they had received approval from the Drug Controller General of India (DCGI), to proceed with the study of a siRNA therapy in India. According to a statement, this is the ...
 The Hindu2 days ago


LDALL RAJAN 3 LAST Contributed by NAMPA / PTI. Biocon chief Kiran Mazumdar Shaw said, "I know many voices in corporate India who are disappointed. Today we are in a very complex economic environment globally, a strong understanding of global ...
 Namibia Press Agency6 days ago When Biocon chairman Kiran Mazumdar met Malala Yousafzai  Economic Times2 weeks ago Biocon-Mylan to file 4 drug applications in FY17 under rev-share  Money Control2 weeks ago Biosimilar insulin Glargine to make $100 m from FY18: Biocon  Money Control1 month ago

SpiceJet, Rel Defence, Biocon up 1-8% after govt ups FDI limit

It has approved 49 percent FDI in defence under automatic rule but FDI above 49 percent in defence is approved through government route on case-to-case basis.
 Money Control5 days ago Karnataka to see more global investments as govt permits 74% FDI under automatic route for Brownfield projects  PharmaBiz3 days ago FDI up to 74% in brownfield pharma under automatic route [Seven Days (United Arab Emirates)]  Pharmacy Choice3 days ago Sweet pill for pharmaceutical sector [Seven Days (United Arab Emirates)]  Pharmacy Choice3 days ago
United News of India

Biocon kicks off 7th batch of its flagship program

Bengaluru, June 13 (UNI) Biocon Academy, a Centre of Excellence in Advanced Biosciences Learning, kicked off the 7th batch of its 16 week Biocon KGI certificate program in Biosciences in collaboration with Keck Graduate Institute, California, ...
 United News of India1 week ago Biocon Academy successfully places 180 students and kicks off 7th batch of its Flagship Program  Pocket News Alert.com1 week ago

Efficient IT backbone necessary to deliver full benefit of GST: Kiran Mazumdar Shaw, Biocon

In an interview with , Kiran Mazumdar Shaw , Biocon, shares her views on the GST Bill. Edited excerpts: ET Now: Do you think now there is a serious possibility that finally the seven-year deadlock on GST would be broken? Kiran Mazumdar Shaw: Well, ...
 Economic Times1 week ago
Deccan Chronicle

CSR: Corporates to let Bengaluru lakes breathe

BENGALURU: Taking their social responsibility seriously, several corporate companies, including Biocon, Wipro, the UB group and Mphasis came forward on Monday to revive and protect the remaining 100 odd lakes of Bengaluru and wetlands in cities ...
 Deccan Chronicle1 week ago Corporates come forward to conserve, rejuvenate Bengaluru lakes  Daijiworldcom1 week ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - biocon
Get updated on latest news & your favorite topics right in your inbox!
More     Less